Hua Medicine (Shanghai) Ltd.

2552

KYG4644K1022

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 08:08:06 14/01/2025 GMT			5-day change	1st Jan Change
1.330 ^HKD	0.00%		-5.00%	-8.90%

11-22	Hua Medicine Terminates Commercialization Agreement with Bayer for Type 2 Diabetes Treatment	MT
11-22	Hua Medicine Announces to Terminate the Agreement with Bayer Healthcare Company Limited	CI

Hua Medicine Terminates Commercialization Agreement with Bayer for Type 2 Diabetes Treatment

November 22, 2024 at 12:49 am

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Hua Medicine (Shanghai) Ltd.

Hua Medicine Terminates Commercialization Agreement with Bayer for Type 2 Diabetes Treatment	11-22	MT
Hua Medicine Announces to Terminate the Agreement with Bayer Healthcare Company Limited	11-21	CI
Hua Medicine Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	29/08/24	CI
Hua Medicine Announces Change of Address of Principal Place of Business in Hong Kong	19/07/24	CI
Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03/24	CI
Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024	29/12/23	CI
Hua Medicine Intends to Conduct Trials of Diabetes Drug in US	21/12/23	MT
Hua Medicine Submits Investigational New Drug Application with the U.S. Food and Drug Administration for the 2Nd Generation Glucokinase Allosteric Activator	21/12/23	CI
China Includes Hua Medicine's Type 2 Diabetes Medication in Drug Reimbursement List	14/12/23	MT
Hua Medicine's Unit Receives 800 Million Yuan for Development of Diabetes Drug	22/11/23	MT
Hua Medicine Ltd. Announces Board and Committee Changes	12/10/23	CI
Hua Medicine Ltd., Q2 2023 Earnings Call, Aug 25, 2023	25/08/23
Hua Medicine Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	24/08/23	CI
Hua Medicine Signs Distribution Agreement with Digital Healthcare Platform	11/04/23	MT
Hua Medicine Ltd. Announces Resignation of Mr. Junling Liu as Independent Non-Executive Director and Change in Composition of the Board Committees	30/03/23	CI
Hua Medicine Ltd., 2022 Earnings Call, Mar 30, 2023	30/03/23
Hua Medicine Shrinks Loss in 2022 as Revenue Witnesses a Boost	29/03/23	MT
Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	29/03/23	CI
Hua Medicine Makes 49 Million Yuan of HuaTangNing Sales Since Launch	17/02/23	MT
Hua Medicine Receives 400 Million Yuan in Milestone Payments for Diabetes Treatment	08/02/23	MT
Hua Medicine Ltd. Announces Directorate and Committee Changes	30/12/22	CI
Hua Medicine Announces Demise of Walter Teh-Ming Kwauk, an Independent Non-Executive Director	24/11/22	CI
Hua Medicine Unit Buys 100% Stake in Diabetes Drug Research Company	18/11/22	MT
China OKs Hua Medicine's New Drug Application for Type 2 Diabetes Treatment; Shares slipped 11%	10/10/22	MT
Hua Medicine Announces Approval of NDA of Huatangning, Innovative First-In-Class GKA Potential Inside Information	09/10/22	CI

Chart Hua Medicine (Shanghai) Ltd.

Duration

Period

2552: Dynamic Chart

Hua Medicine is a China-based company principally engaged in the drug development business. The Company is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The Company mainly operates its business in the domestic and overseas markets.

Employees

172

Sector

Biotechnology & Medical Research

Calendar

12/03/2025 - Q4 2024 Earnings Release (Projected)

More about the company